.
the software identified and measured a marker of svd and then gave a score indicating how severe the disease was ranging from mild to severe.
.
.
eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
https://grassfed.us/Grierson-father-of-Knowiton-from-Gteborg ![]()
.